The state of New York currently has 221 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including New York, Rochester, Bronx and Buffalo.
Diabetes Care for Breast Cancer Patients
Recruiting
The goal of this study is to find a new way to make diabetes care better for patients with breast cancer and diabetes who are currently receiving cancer treatment. We will have two groups, the researchers will decide who is in which group. One group will be working with a nurse who is trained in diabetes care while the other does not. This will allow the investigators to see if having a trained nurse as part of the care team can help improve the care the patients receive.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York +2 locations
Conditions: Breast Cancer, PreDiabetes, Type 2 Diabetes
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
Recruiting
The purpose of this study is to see whether providing radiation on a shortened (compressed) schedule of 5 days in a row is a safe and effective approach to prevent cancer from coming back in people who have had a mastectomy.
Gender:
All
Ages:
30 years and above
Trial Updated:
02/21/2024
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Invasive Breast Cancer, Post-mastectomy
The Effect of Acupuncture on Cancer-Related Cognitive Difficulties
Recruiting
The purpose of this study is to test whether acupuncture can improve cognitive difficulties and insomnia in survivors of breast cancer. Researchers will compare the effects of real acupuncture with those of placebo acupuncture and wait-list acupuncture. This study will also look at insomnia's link to cognitive difficulties. All study participants (receiving real acupuncture, placebo acupuncture, or wait-list acupuncture) will complete study questionnaires and/or have cognitive testing at Weeks... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack, New York +3 locations
Conditions: Breast Cancer
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Recruiting
This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Gender:
Female
Ages:
Between 18 years and 90 years
Trial Updated:
02/20/2024
Locations: Mount Sinai Beth Israel, New York, New York +2 locations
Conditions: Breast Cancer, Metastasis
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Recruiting
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: NGM Clinical Study Site, New York, New York
Conditions: Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study
Recruiting
The purpose of this study is to test, customize, and personalize a mobile app-based intervention program in order to help rare and breast cancer survivors cope with fears of cancer recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Breast Cancer, Rare Cancer
IMPACT Trial: Intervention to iMProve AdherenCe Equitably
Recruiting
To determine the efficacy of a multicomponent adherence intervention among participants with early-stage breast cancer on endocrine therapy and at least one oral cardiovascular disease (CVD) medication on adherence to endocrine therapy and to CVD medication at 24 weeks assessed by self-report using the Domains of Subjective Extent (DOSE)-Nonadherence questionnaire and also by pharmacy fill data assessed in the electronic health record (EHR).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
02/02/2024
Locations: Columbia University Medical Center, New York, New York
Conditions: Breast Cancer
Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer
Recruiting
Cancer and depression commonly occur together, and each worsens the other. We conducted a large psychotherapy study treating depression in breast cancer patients, showing that psychotherapy lowers symptoms. Surprisingly, no studies have compared depression-focused psychotherapy to antidepressant medication for patients with breast cancer and depression. We applied to the National Cancer Institute for a large, cross-national grant. Reviewers asked us to first demonstrate that patients would accep... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/01/2024
Locations: Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York
Conditions: Major Depressive Disorder, Breast Cancer, Venlafaxine
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
Recruiting
The researchers are doing this study to look at changes in Ki67 expression after at least 2 weeks of endocrine therapy in people with ER+/HER2- breast cancer undergoing cancer removal surgery. Participants will receive the endocrine therapy before their surgery. The researchers will look at how changes in Ki67 expression compare between participants who are carriers of the BRCA2 mutation and participants who are noncarriers of the BRCA2 mutation.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Breast Cancer
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
Recruiting
The purpose of this study is to see how the cancer treatment affects the ovaries. Cancer treatment can make it hard for a person to conceive a child in the future. It may also bring on early menopause. We will check blood levels of hormones that the ovaries produce. We will do this before, during, and after the cancer treatment. We will also ask the patient to fill out questionnaires about their menstrual cycle (periods) and information about your health and pregnancies. This may help us learn w... Read More
Gender:
Female
Ages:
Between 18 years and 44 years
Trial Updated:
02/01/2024
Locations: Memorial Sloan Kettering Commack, Commack, New York +4 locations
Conditions: Breast Cancer
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
Recruiting
The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES PET/CT brain scan will be completed before this standard of care radiation treatment. Patients will be followed prospectively with clinical and MRI assessments per standard-of-care for a total of 12 m... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: New York-Presbyterian/Weill Cornell Medical Center, New York, New York
Conditions: Breast Cancer, Brain Metastases
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
Recruiting
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Roswell Park, Buffalo, New York +2 locations
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer